Results 91 to 100 of about 2,224,846 (160)

Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma

Neoplasia: An International Journal for Oncology Research, 2016
BACKGROUND: Extensive cross talk exists between PI3K/Akt/mTOR and mitogen-activated protein kinase (MAPK) pathways, and both are upregulated in pancreatic ductal adenocarcinoma (PDAC).
Matthew H. Wong, Aiqun Xue, Robert C. Baxter, Nick Pavlakis, Ross C. Smith   +4 more
doaj   +1 more source

Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer [PDF]

, 2016
Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through the secondary T790M EGFR mutation.
Tang, H, Roy, Rajat, Hu, Yili, Liu, Z, Pardo, OE, Li, H, Heynen, GJ, Seckl, MJ, de Bruin, Elza, Smit, EF, Heynen, Guus Jje, Chater, E, Tang, Huiru, Pardo, Olivier E, Stokes, W, Downward, Julian, Seckl, Michael J, Heynen, GJJE, Chater, Emily, Roy, R, Wang, Y, Liu, Zhigang, Stokes, William, Smit, Egbert F, Downward, J, Wang, Yulan, de Bruin, E, Hu, Y, Li, Hongde, Seckl, MJS   +29 more
core   +1 more source

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.

, 2016
Erlotinib has demonstrated poor clinical response rates for head and neck squamous cell carcinoma (HNSCC) to date and the majority of respondents acquire resistance to erlotinib relatively quickly.
Gibson-Corley, Katherine N, Ihejirika, Nnamdi, Simons, Andrean L, Stanam, Aditya, Love-Homan, Laurie   +4 more
core   +1 more source

Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050 [PDF]

Background: Antimicrobial resistance (AMR) poses an important global health challenge in the 21st century. A previous study has quantified the global and regional burden of AMR for 2019, followed with additional publications that provided more detailed ...
GBD, 2021 Antimicrobial Resistance Collaborators, GBD 2021 Antimicrobial Resistance Collaborators   +1 more
core   +1 more source

Erlotinib resistance in Lung Cancer: Current Progress and Future Perspectives [PDF]

, 2013
Lung cancer is the most common cancer in the world. Despite modern advancements in surgeries, chemotherapies and radiotherapies over the past few years, lung cancer still remains a very difficult disease to treat.
Joy eTang, Fazlul H. Sarkar, Rasha Salama, Aamir Ahmad, Rasha eSalama, Shirish M. Gadgeel, Fazlul H Sarkar, Shirish M Gadgeel, Aamir eAhmad, Joy Tang   +9 more
core   +1 more source

Abstract 3142: Aberrantly expressed microRNAs drive the development of acquired Erlotinib resistance in non-small cell lung cancer

, 2017
Lung cancer is the leading cause of cancer-related deaths in the world. Non-small cell lung cancer (NSCLC) accounts for ~85% of the cases. NSCLC patients frequently harbor causal gene mutations.
Alejandra Agredo, Andrea L. Kasinski, Arpita S. Pal   +2 more
core   +1 more source

The transcriptional repressor Delta EF1 controls resistance to the EGFR inhibitor erlotinib in human HNSCC lines

, 2009
Epidermal Growth Factor Receptor (EGFR) overexpression occurs in about 90% of Head and Neck Squamous Cell Carcinoma (HNSCC) cases. Aberrant EGFR signaling has been implicated in the malignant features of HNSCC.
Haddad, Yasmine
core   +1 more source

Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non–small-cell lung cancer

Tumor Biology, 2017
Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors, such as gefitinib and erlotinib, is a critical issue in the treatment of patients with epidermal growth factor receptor mutant–positive non–small-cell lung cancer. Recent
Huake Sun, Huiwen Ma, Jianmin Wang, Liqin Xia, Guangkuo Zhu, Zhoufei Wang, Jianguo Sun, Zhengtang Chen   +7 more
doaj   +1 more source

Correction: M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way. [PDF]

J Exp Clin Cancer Res, 2023
Li K, Peng ZY, Gao S, Wang QS, Wang R, Li X, Xiao GD, Zhang J, Ren H, Tang SC, Sun X.   +10 more
europepmc   +1 more source

Abstract 4163: Blockade of the interleukin-1 signaling pathway overcomes erlotinib resistance in head and neck cancer cells

, 2017
The EGFR tyrosine kinase inhibitor erlotinib has demonstrated poor clinical response rates for head and neck squamous cell carcinoma (HNSCC) to date and the majority of respondents acquire resistance to erlotinib relatively quickly. Our previous data has
Andrean L. Simons, Aditya Stanam, Katherine N. Gibson-Corley   +2 more
core   +1 more source